Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants. Uses
Basiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents. It has been reported that some cases of lichen planus have been successfully treated with basiliximab as an alternative therapy to cyclosporin. No short-term side effects have been reported. Mechanism of action
Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant. Chemistry
It is a chimeric CD25 monoclonal antibody of the IgG1 isotype. History
It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998. See also
Daclizumab


== References and notes ==
Treatment
Initial treatments for minor erythrasma can begin with keeping the area clean and dry and with antibacterial soaps. The next level is treated with topical fusidic acid and an antibacterial solution such as clindamycin to eradicate the bacteria. For aggressive types of erythrasma, oral antibiotics such as macrolides (erythromycin or azithromycin) can be prescribed. Below is a figure showing the different types and subtypes of therapies. There is no agreement on the best treatment for this disease. There are many limitations on these treatments such as more irritation, possible allergic reactions, and ulcerations. These treatments are suitable for most ages, but for young children it should be monitored very closely. Prognosis
Erythrasma has a good prognosis if it is discovered early and properly treated. In more severe cases, it can be an indicator for another disease such as diabetes mellitus. See also
List of cutaneous conditions
Athletes foot
Tinea pedis
Woods lamp
Type 2 diabetes mellitus

References
Further reading
eMedicine
Hamann K, Thorn P (1991). "Systemic or local treatment of erythrasma? A comparison between erythromycin tablets and Fucidin cream in general practice". Scand J Prim Health Care. 9 (1): 35–9. doi:10.3109/02813439109026579. PMID 2041927. == External links ==